Compugen Ltd. reported its financial results for the second quarter ended June 30, 2025, with revenues of approximately $1.3 million. This represents a decrease from $6.7 million in the comparable period of 2024, primarily due to the timing of recognizing portions of upfront and milestone payments from the Gilead license agreement and an AstraZeneca clinical milestone in the prior year.
The company reported a net loss of approximately $7.3 million, or $0.08 per basic and diluted share, for Q2 2025. This is an increase from a net loss of approximately $2.1 million, or $0.02 per basic and diluted share, in the second quarter of 2024.
As of June 30, 2025, Compugen held approximately $93.9 million in cash, cash equivalents, and investments. The company reiterated its expectation that this cash position will be sufficient to fund its operating plans into 2027, without including any additional cash inflows, providing financial stability despite the quarterly revenue decline.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.